Merck's Keytruda takes home adjuvant win in melanoma, escalating early-line fight with Bristol Myers

Keytruda beat out placebo in staving off the recurrence of cancer as an adjuvant therapy in patients with high-risk stage II melanoma after surgery to remove their tumors, according to topline data from the KEYNOTE-716 study released Thursday.